{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:38:29Z","timestamp":1787647109565,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Hodgkin's lymphoma (HL) survivors who undergo radiotherapy experience increased risks of second cancers (SC) and cardiac sequelae. To reduce such risks, extended-field radiotherapy (RT) for HL has largely been replaced by involved field radiotherapy (IFRT). While it has generally been assumed that IFRT will reduce SC risks, there are few data that quantify the reduction in dose to normal tissues associated with modern RT practice for patients with mediastinal HL, and no estimates of the expected reduction in SC risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Organ-specific dose-volume histograms (DVH) were generated for 41 patients receiving 35 Gy mantle RT, 35 Gy IFRT, or 20 Gy IFRT, and integrated organ mean doses were compared for the three protocols. Organ-specific SC risk estimates were estimated using a dosimetric risk-modeling approach, analyzing DVH data with quantitative, mechanistic models of radiation-induced cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Dose reductions resulted in corresponding reductions in predicted excess relative risks (ERR) for SC induction. Moving from 35 Gy mantle RT to 35 Gy IFRT reduces predicted ERR for female breast and lung cancer by approximately 65%, and for male lung cancer by approximately 35%; moving from 35 Gy IFRT to 20 Gy IFRT reduces predicted ERRs approximately 40% more. The median reduction in integral dose to the whole heart with the transition to 35 Gy IFRT was 35%, with a smaller (2%) reduction in dose to proximal coronary arteries. There was no significant reduction in thyroid dose.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The significant decreases estimated for radiation-induced SC risks associated with modern IFRT provide strong support for the use of IFRT to reduce the late effects of treatment. The approach employed here can provide new insight into the risks associated with contemporary IFRT for HL, and may facilitate the counseling of patients regarding the risks associated with this treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1748-717x-2-13","type":"journal-article","created":{"date-parts":[[2007,5,2]],"date-time":"2007-05-02T15:30:31Z","timestamp":1178119831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":123,"title":["A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk"],"prefix":"10.1186","volume":"2","author":[{"given":"Eng-Siew","family":"Koh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Heydarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer K","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melania","family":"Pintilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narinder","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,1]]},"reference":[{"key":"61_CR1","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","volume":"20","author":"GM Dores","year":"2002","unstructured":"Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB: Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002, 20: 3484-3494. 10.1200\/JCO.2002.09.038","journal-title":"J Clin Oncol"},{"key":"61_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0167-8140(97)00125-4","volume":"46","author":"C Glanzmann","year":"1998","unstructured":"Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P: Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother Oncol 1998, 46: 51-62. 10.1016\/S0167-8140(97)00125-4","journal-title":"Radiother Oncol"},{"key":"61_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.6004\/jnccn.2006.0022","volume":"4","author":"J Yahalom","year":"2006","unstructured":"Yahalom J: Favorable early-stage Hodgkin lymphoma. J Natl Compr Canc Netw 2006, 4: 233-240.","journal-title":"J Natl Compr Canc Netw"},{"key":"61_CR4","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","volume":"100","author":"AK Ng","year":"2002","unstructured":"Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100: 1989-1996. 10.1182\/blood-2002-02-0634","journal-title":"Blood"},{"key":"61_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","volume":"95","author":"FE van Leeuwen","year":"2003","unstructured":"van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS: Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95: 971-980.","journal-title":"J Natl Cancer Inst"},{"key":"61_CR6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","volume":"18","author":"AJ Swerdlow","year":"2000","unstructured":"Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18: 498-509.","journal-title":"J Clin Oncol"},{"key":"61_CR7","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1001\/jama.290.4.465","volume":"290","author":"LB Travis","year":"2003","unstructured":"Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr., Gilbert E: Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290: 465-475. 10.1001\/jama.290.4.465","journal-title":"JAMA"},{"key":"61_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","volume":"159","author":"ES Gilbert","year":"2003","unstructured":"Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, Joensuu T, Lynch CF, Curtis RE, Holowaty E, Storm H, Pukkala E, van't Veer MB, Fraumeni JF, Boice JD Jr., Clarke EA, Travis LB: Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 2003, 159: 161-173. 10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","journal-title":"Radiat Res"},{"key":"61_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0360-3016(94)00605-K","volume":"33","author":"DB Hughes","year":"1995","unstructured":"Hughes DB, Smith AR, Hoppe R, Owen JB, Hanlon A, Wallace M, Hanks GE: Treatment planning for Hodgkin's disease: a patterns of care study. Int J Radiat Oncol Biol Phys 1995, 33: 519-524. 10.1016\/0360-3016(94)00605-K","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"61_CR10","first-page":"2043","volume-title":"Principles and Practice of Radiation Oncology","author":"RT Hoppe","year":"2004","unstructured":"Hoppe RT: Hodgkin's Disease. In Principles and Practice of Radiation Oncology. 6th edition. Edited by: Perez CA. Philadelphia., Lippincott Williams and Wilkins.; 2004:2043-2063.","edition":"6th"},{"key":"61_CR11","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1182\/blood.V106.11.814.814","volume":"106","author":"E Eghbali","year":"2005","unstructured":"Eghbali E Brice P, Cremmers G-Y, Henry-Amar, M et al. EORTC Lymphoma Group.: Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial. Blood 2005, 106: 814.","journal-title":"Blood"},{"key":"61_CR12","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1182\/blood.V106.11.2673.2673","volume":"106","author":"A Engert","year":"2005","unstructured":"Engert A Pluetschow A, Eich, HT, Diehl V et al.: Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin\u2019s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). Blood 2005, 106: 2673.","journal-title":"Blood"},{"key":"61_CR13","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1093\/annonc\/mdl302","volume":"17","author":"J Franklin","year":"2006","unstructured":"Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Ferme C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J: Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006, 17: 1749-60. 10.1093\/annonc\/mdl302","journal-title":"Ann Oncol"},{"key":"61_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.clon.2004.07.004","volume":"17","author":"PJ Hoskin","year":"2005","unstructured":"Hoskin PJ, Smith P, Maughan TS, Gilson D, Vernon C, Syndikus I, Linch DC: Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 2005, 17: 47-53.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"61_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/0360-3016(91)90296-G","volume":"21","author":"DL Zellmer","year":"1991","unstructured":"Zellmer DL, Wilson JF, Janjan NA: Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys 1991, 21: 1343-1351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"61_CR16","first-page":"8","volume-title":"Cellular Radiation Biology","author":"LH Gray","year":"1965","unstructured":"Gray LH: A Symposium Considering Radiation Effects in the Cell and Possible Implications for Cancer Therapy, a Collection of Papers. In Cellular Radiation Biology. Baltimore, Williams & Wilkins; 1965:8-25."},{"key":"61_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1259\/0007-1285-48-567-157","volume":"48","author":"RH Mole","year":"1975","unstructured":"Mole RH: Ionizing radiation as a carcinogen: practical questions and academic pursuits The Silvanus Thompson Memorial Lecture delivered at The British Institute of Radiology on April 18, 1974. Br J Radiol 1975, 48: 157-169.","journal-title":"Br J Radiol"},{"key":"61_CR18","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1093\/jnci\/dji290","volume":"97","author":"LB Travis","year":"2005","unstructured":"Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr., Gilbert E, Gail MH: Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005, 97: 1428-1437.","journal-title":"J Natl Cancer Inst"},{"key":"61_CR19","doi-asserted-by":"publisher","first-page":"13040","DOI":"10.1073\/pnas.0506648102","volume":"102","author":"RK Sachs","year":"2005","unstructured":"Sachs RK, Brenner DJ: Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci U S A 2005, 102: 13040-13045. 10.1073\/pnas.0506648102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"61_CR20","volume-title":"Radiation Field Design and Dose in Hodgkin's Disease and Non-Hodgkin's Lymphoma:New Concepts","author":"J Yahalom","year":"2004","unstructured":"Yahalom J: Radiation Field Design and Dose in Hodgkin's Disease and Non-Hodgkin's Lymphoma:New Concepts, New Tools.: ; Atlanta, Georgia. ; 2004."},{"key":"61_CR21","unstructured":"The Visible Human Project. National Library of Medicine. National Institutes of Health. Access date:February 1, 2005.[http:\/\/www.nlm.nih.gov\/research\/visible\/animations.html]"},{"key":"61_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr., Boice JD Jr., Gilbert E: Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002, 94: 182-192.","journal-title":"J Natl Cancer Inst"},{"key":"61_CR23","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","volume":"270","author":"SL Hancock","year":"1993","unstructured":"Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993, 270: 1949-1955. 10.1001\/jama.270.16.1949","journal-title":"JAMA"},{"key":"61_CR24","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2307\/3572009","volume":"29","author":"GA Sacher","year":"1966","unstructured":"Sacher GA, Trucco E: Theory of radiation injury and recovery in self-renewing cell populations. Radiat Res 1966, 29: 236-256. 10.2307\/3572009","journal-title":"Radiat Res"},{"key":"61_CR25","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2307\/3578892","volume":"137","author":"DE Thompson","year":"1994","unstructured":"Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Izumi S, et al.: Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 1994, 137: S17-67. 10.2307\/3578892","journal-title":"Radiat Res"},{"key":"61_CR26","volume-title":"Report of the NCI-CDC Working Group to Revise the 1985 NIH Radioepidemiological Tables. DHHS Publication No. 03-5387 NIH Bethesda, MD","author":"E Land CE Gilbert","year":"2003","unstructured":"Land CE Gilbert E, Smith JM, Hoffman FO, Apostoiae I, Thomas B and Kocher D .: Report of the NCI-CDC Working Group to Revise the 1985 NIH Radioepidemiological Tables. DHHS Publication No. 03-5387 NIH Bethesda, MD. 2003."},{"key":"61_CR27","unstructured":"NRC. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Academy of Sciences.[http:\/\/www.nap.edu]"},{"key":"61_CR28","unstructured":"Interactive RadioEpidemiological Program, IREP version 5.3. 2005."},{"key":"61_CR29","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","volume":"21","author":"BM Aleman","year":"2003","unstructured":"Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003, 21: 3431-3439. 10.1200\/JCO.2003.07.131","journal-title":"J Clin Oncol"},{"key":"61_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1080\/02841860310013346","volume":"42","author":"A Gustavsson","year":"2003","unstructured":"Gustavsson A, Osterman B, Cavallin-Stahl E: A systematic overview of radiation therapy effects in Hodgkin's lymphoma. Acta Oncol 2003, 42: 589-604. 10.1080\/02841860310013346","journal-title":"Acta Oncol"},{"key":"61_CR31","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","volume":"290","author":"MC Hull","year":"2003","unstructured":"Hull MC, Morris CG, Pepine CJ, Mendenhall NP: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290: 2831-2837. 10.1001\/jama.290.21.2831","journal-title":"JAMA"},{"key":"61_CR32","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1182\/blood-2005-04-1535","volume":"106","author":"DA Hill","year":"2005","unstructured":"Hill DA, Gilbert E, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer M, Storm H, Pukkala E, Stovall M, Curtis RE, Allan JM, Boice JD, Travis LB: Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood 2005, 106: 3358-3365. 10.1182\/blood-2005-04-1535","journal-title":"Blood"},{"key":"61_CR33","volume-title":"Radiobiology for the Radiologist","author":"EJ Hall","year":"2000","unstructured":"Hall EJ: Radiobiology for the Radiologist. Philadelphia, Lippincott, Williams & Wilkins; 2000."},{"key":"61_CR34","volume-title":"Clinical Radiobiology","author":"AHWDW Nias","year":"1988","unstructured":"Nias AHWD W.: Clinical Radiobiology. Edinburgh, Churchill Livingstone; 1988."},{"key":"61_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2","volume":"79","author":"AC Aisenberg","year":"1997","unstructured":"Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997, 79: 1203-1210. 10.1002\/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2","journal-title":"Cancer"},{"key":"61_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0360-3016(01)02701-8","volume":"52","author":"RW Tsang","year":"2002","unstructured":"Tsang RW, Gospodarowicz MK, O'Sullivan B: Staging and management of localized non-Hodgkin's lymphomas: variations among experts in radiation oncology. Int J Radiat Oncol Biol Phys 2002, 52: 643-651. 10.1016\/S0360-3016(01)02701-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"61_CR37","first-page":"262","volume":"13","author":"AM Moody","year":"2001","unstructured":"Moody AM, Pratt J, Hudson GV, Smith P, Lamont A, Williams MV: British National Lymphoma Investigation: pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease. Clin Oncol (R Coll Radiol) 2001, 13: 262-268.","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-2-13.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T01:06:50Z","timestamp":1630458410000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-2-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["61"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-2-13","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"15 November 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"13"}}